Advertisement
Screener

VAXCYTE, INC. (PCVX) ROA

Vaxcyte, Inc. ROA

Return on assets (ROA) is the profit a company earns for every dollar of assets it uses, shown as a percentage. It is net income divided by total assets, and the table shows both amounts. Because assets are funded by lenders as well as shareholders, ROA is not inflated by borrowing the way ROE can be, and it is naturally lower for businesses that need many factories, stores or other assets. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Vaxcyte, Inc. roa for the quarter ending 2026-06-30 was -33.91%, a change of -17.35% year-over-year.
  • Vaxcyte, Inc. roa for the quarter ending 2026-03-31 was -28.27%, a change of -13.18% year-over-year.
  • Vaxcyte, Inc. roa for the quarter ending 2025-12-31 was -25.53%, a change of -12.32% year-over-year.
  • Vaxcyte, Inc. roa for the quarter ending 2025-09-30 was -20.72%, a change of -6.46% year-over-year.
  • Vaxcyte, Inc. roa for fiscal 2025 was -25.53%, a change of -12.32% from fiscal 2024.
  • Vaxcyte, Inc. roa for fiscal 2024 was -13.21%, a change of 15.36% from fiscal 2023.
  • Vaxcyte, Inc. roa for fiscal 2023 was -28.57%, a change of -6.36% from fiscal 2022.
  • Vaxcyte, Inc. roa for fiscal 2022 was -22.21%, a change of 8.64% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical ROA

DateROANet income 12 monthNet income 3 monthTotal assets
2026-06-30-33.91%-$1.06B-$284.30M$3.14B
2026-03-31-28.27%-$946.53M-$320.62M$3.35B
2025-12-31-25.53%-$766.63M$519.35M$3B
2025-09-30-20.72%-$657.2M-$212.83M$3.17B
2025-06-30-16.56%-$547.5M-$166.57M$3.31B
2025-03-31-15.09%-$509.63M-$140.72M$3.38B
2024-12-31-13.21%-$463.93M$326.38M$3.51B
2024-09-30-14.26%-$507.65M-$103.12M$3.56B
2024-06-30-23.82%-$497.19M-$128.70M$2.09B
2024-03-31-20.89%-$436.82M-$95.02M$2.09B
2023-12-31-28.57%-$402.27M$221.06M$1.41B
2023-09-30-20.02%-$299.52M-$92.66M$1.5B
2023-06-30-17.62%-$264.77M-$68.34M$1.5B
2023-03-31-24.30%-$244.96M-$60.46M$1.01B
2022-12-31-22.21%-$223.49M$145.21M$1.01B
2022-09-30-42.23%-$174M-$57.92M$412.07M
2022-06-30-34.67%-$142.7M-$48.53M$411.62M
2022-03-31-29.26%-$117.84M-$38.99M$402.72M
2021-12-31-30.86%-$100.08M$71.41M$324.34M
2021-09-30-26.05%-$92.25M-$26.61M$354.07M
2021-06-30-24.20%-$86.65M-$23.68M$358.05M
2021-03-31-21.78%-$83.3M-$21.22M$382.35M
2020-12-31-22.71%-$89.22M-$20.74M$392.83M
2020-09-30-20.58%-$83.1M-$21.02M$403.82M
2020-06-30-17.63%-$73.4M-$20.32M$416.25M
2019-12-31-76.52%-$50.27M-$14.62M$65.7M

Annual ROA

DateROANet income 12 monthTotal assets
2025-12-31-25.53%-$766.63M$3B
2024-12-31-13.21%-$463.93M$3.51B
2023-12-31-28.57%-$402.27M$1.41B
2022-12-31-22.21%-$223.49M$1.01B
2021-12-31-30.86%-$100.08M$324.34M
2020-12-31-22.71%-$89.22M$392.83M
2019-12-31-76.52%-$50.27M$65.7M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68